10 results on '"Brau, Norbert"'
Search Results
2. Safety and Efficacy of Glecaprevir/Pibrentasvir in Adults with Chronic Hepatitis C Virus Infection Genotype 1 and 6 and Chronic Kidney Disease: An Integrated Analysis
3. Su1415 The Tolerability of Sof/VEL for 12 Weeks in >1000 Patients Treated in the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies: An Integrated Safety Analysis
4. 499 Ribavirin-Free Regimen With Velpatasvir and Sofosbuvir is Associated With High Efficiency and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From ASTRAL-2 and 3 Clinical Trials
5. 510 - Safety and Efficacy of Glecaprevir/Pibrentasvir in Adults with Chronic Hepatitis C Virus Infection Genotype 1 and 6 and Chronic Kidney Disease: An Integrated Analysis
6. 424 - SOF/VEL/VOX Results in High SVR12 Rates when Administered for 12 Weeks in Daa-Experienced Patients or for 8 Weeks in Daa-Naïve Patients: An Integrated Analysis of the POLARIS-1, POLARIS-2, POLARIS-3 and POLARIS-4 Studies
7. Tu2038 All Oral Fixed-dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: The Phase 3 ION-1 Study
8. Infections During Peginterferon (pegIFN)/Ribavirin (RBV) Therapy Are Associated With a Decline in Lymphocyte Count: Results of the IDEAL Study
9. Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: A trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy relapsers: Final results
10. Once-weekly recombinant human erythropoetin (Epoetin alfa) facilitates optimal ribavirin (RBV) dosing in hepatitis C virus (HCV)-infected patients receiving interferon-α-2b (IFN)/RBV combination therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.